All News

A new boxed warning has been added to the labeling for five gadolinium-based contrast agents used to improve the visibility of internal structures during MRI scans. This came after the FDA received reports of the risk of developing nephrogenic systemic fibrosis (NSF), a potentially fatal disease causing thickening of the skin and connective tissues that inhibits their movement.

Home Diagnostics has launched TrackRecord Data Management Software, an electronic diabetes management system. The system is designed for use with Home Diagnostics' blood glucose meters and will enable people with diabetes and healthcare professionals who treat them to better understand how various lifestyle and behavior choices impact blood glucose levels.

RESTAT, a PBM, will now make its data available on RxHub's national patient health information network to provide access to patient prescription information nationwide.

CMS is now soliciting bids for the first round of the Medicare Durable Medical Equipment, Prosthetics, Orthotics & Supplies (DMEPOS) Competitive Bidding Program.

More than a week after the initial deadline for registering for a National Provider Identifier (NPI) number passed, CMS released a dissemination notice that reveals that a key NPI database will be available soon.

Changes have been made to the prescribing information for deferasirox (Exjade, Novartis) following postmarketing reports of acute renal failure and cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia.

The Consumer Healthcare Products Association (CHPA) applauded recent actions taken by many major retailers to prevent children under age 18 from purchasing OTC cough medicines that contain dextromethorphan.

The FDA said it will wait to further evaluate data submitted by manufacturer GlaxoSmithKline regarding the safety of its diabetes drug rosiglitazone (Avandia).

Low molecular weight heparin, enoxaparin (Lovenox, Sanofi-Aventis), has a new indication, the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).

You'll be seeing a lot of the term downstream entity. That's the handle CMS proposes to use to signify pharmacies or pharmacists who contract with PBMs, dubbed first-tier entities, that, in turn, contract with Part D plan sponsors.

New immunosuppressive regimens that combine Certican and low-dose Neoral to preverse renal function following heart transplants and Viagra to lower pulmonary arterial heypertension are coming soon to hospitals.

Updated studies show that the greater use of life-enhancing highly active antiretroviral therapy, the more reports proliferate of unusal side effects, including lipodystrophy, lactic acidosis, insulin resistance, and recently, male osteoporosis.

The FDA approved a new treatment to help cure bacterial conjunctivitis, or pink eye, with the approval of azithromycin ophthalmic solution 1% (AzaSite) from Inspire Pharmaceuticals.

FDA has approved Neupro patch designed to treat symptoms of early Parkinson's disease. Consistent and continuous drug delivery over a 24-hour period may prove to be an advantage of this patch.

The emergence of any vaccine is a complicated event, necessitating physician, pharmacist, and public education and the creation of formulary protocols. But when a drug directly involves issues surrounding the sexual activity of underage girls, complexity devolves into controversy.

Women have more birth control choices than ever before. Oral contraceptives are vastly different from the pills that hit the market 40 years ago. New forms of contraception such as Plan B are gaining in popularity.